OTC: BXPHF - Botanix Pharmaceuticals Limited

Yield per half year: +2 405.88%
Sector: Healthcare

Share chart Botanix Pharmaceuticals Limited

Extended chart Simple chart
Financial Markets by TradingView

About

Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia. The company engages in development of novel treatments for common skin diseases and infections.

More details
Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIb clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase IIb clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. The company was incorporated in 1984 and is based in Leederville, Australia.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

EBITDA -0.012
EV/EBITDA 0.2763
Industry Biotechnology
P/BV 1.72
P/S 5.37
Sector Health Care
Валюта usd
Валюта отчета aud
Выручка 0.0033
Сайт https://www.botanixpharma.com
Цена ао 0.289
Число акций ао 1.15395 млрд
Change price per day: +0.2353% (0.2125)
Change price per week: -9.36% (0.235)
Change price per month: -21.4% (0.271)
Change price per 3 month: -13.41% (0.246)
Change price per half year: +2 405.88% (0.0085)
Change price per year: -29% (0.3)
Change price per 3 year: +281.04% (0.0559)
Change price per year to date: -29% (0.3)
All parameters

Underestimation

Title Value Grade
P/S 72.56 1
P/BV 1.38 9
P/E 0 0
EV/EBITDA -5.1 0
Total: 4.13

Efficiency

Title Value Grade
ROA, % -12.35 0
ROE, % -12.78 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0.1372

Debt

Title Value Grade
Debt/EBITDA -0.0059 10
Total: 7.6

Growth impulse

Title Value Grade
Yield Revenue, % -59.07 0
Yield Ebitda, % 25.47 4
Yield EPS, % 56.82 7
Total: 3
More



Head Job title Payment Year of birth
Mr. Vincent P. Ippolito MD & Executive Chairman 244.45k 1959 (65 years)
Dr. Howie McKibbon Chief Executive Officer 393.72k
Mr. Matthew Callahan L.L.B., M.B.A., MBA LLB Executive Director 258.29k 1973 (51 year)
Dr. Jack Hoblitzell Ph.D. Senior Vice President of Pharmaceutical Development N/A
Dr. Patricia S. Walker M.D., Ph.D. Chief Medical Adviser N/A 1959 (65 years)
Dr. Boris Meyerson Ph.D. Chief Business Officer
Mr. David Morgan Head of Corporate Affairs
Mr. Graeme Morissey Chief Financial Officer

Address: Australia, West Perth, 41 – 47 Colin Street - open in Google maps, open in Yandex maps
Website: https://www.botanixpharma.com